Fresenius To Buy 51% Of Indonesia Drug Maker For Estimated $200 Million
This article was originally published in PharmAsia News
Fresenius Kabi said it plans to buy a controlling interest in Indonesia's PT Ethica Industri Farmasi in a deal that could be worth as much as $200 million.
You may also be interested in...
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.